IDEAYA Biosciences (IDYA) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.88
- EPS estimate
- −$0.78
- EPS surprise
- −12.56%
- Revenue surprise
- −100.00%
- Revenue
- $0.00
- Revenue estimate
- $4.2M
- Reported
- Aug 5, 2025
IDEAYA Biosciences' most recent quarter in the table is Q2 2025, reported on August 5, 2025. The company posted a loss of $0.88 per share, wider than the $0.78 loss analysts expected, a 12.56% miss. Revenue had been estimated at $4.2 million, but no revenue figure is recorded for the quarter. Compared with Q2 2024, the loss per share widened from $0.68, about 29%.
Losses have grown over the table's history. The annual loss was $1.39 per share in both 2021 and 2022, then $1.97 in 2023 and $3.30 in 2024. The widest quarterly loss was Q4 2024, at $1.49 per share. The only profitable quarter shown is Q3 2022, at $0.04 per share, when revenue reached $29.7 million, the highest in the table. Most other quarters brought between $3.0 million and $11.4 million where a figure is given. Over the 20 quarters shown, IDEAYA beat the EPS estimate nine times and missed 11 times, including each of the last two quarters.
The table has no results after Q2 2025. In earlier years, Q3 results came out in early or mid November. Newer quarters will show whether the loss per share kept widening.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 5, 2025 | −$0.78 | −$0.88 | −12.56% | $0.00 | SEC |
| Q1 2025 | May 6, 2025 | −$0.66 | −$0.82 | −24.04% | $0.00 | SEC |
| Q4 2024 | Feb 13, 2025 | −$0.63 | −$1.49 | −136.96% | $7.0M | SEC |
| Q3 2024 | Nov 4, 2024 | −$0.65 | −$0.60 | +7.36% | $0.00 | SEC |
| Q2 2024 | Aug 6, 2024 | −$0.54 | −$0.68 | −26.96% | $0.00 | SEC |
| Q1 2024 | May 7, 2024 | −$0.52 | −$0.53 | −2.89% | $0.00 | SEC |
| Q4 2023 | Feb 20, 2024 | −$0.47 | −$0.52 | −11.18% | $3.9M | SEC |
| Q3 2023 | Nov 7, 2023 | −$0.49 | −$0.46 | +5.95% | $8.0M | SEC |
| Q2 2023 | Aug 10, 2023 | −$0.55 | −$0.50 | +9.39% | $3.5M | SEC |
| Q1 2023 | May 9, 2023 | −$0.54 | −$0.49 | +9.49% | $7.9M | SEC |
| Q4 2022 | Mar 7, 2023 | −$0.56 | −$0.50 | +9.91% | $4.0M | SEC |
| Q3 2022 | Nov 8, 2022 | −$0.61 | $0.04 | +106.60% | $29.7M | SEC |
| Q2 2022 | Aug 15, 2022 | −$0.51 | −$0.57 | −12.85% | $5.9M | SEC |
| Q1 2022 | May 10, 2022 | −$0.41 | −$0.36 | +12.47% | $11.4M | SEC |
| Q4 2021 | Mar 15, 2022 | −$0.31 | −$0.47 | −51.03% | $3.0M | SEC |
| Q3 2021 | Nov 15, 2021 | −$0.30 | −$0.31 | −2.45% | $9.0M | SEC |
| Q2 2021 | Aug 10, 2021 | −$0.07 | −$0.33 | −371.43% | $8.8M | SEC |
| Q1 2021 | May 10, 2021 | −$0.30 | −$0.28 | +5.69% | $7.2M | SEC |
| Q4 2020 | Mar 23, 2021 | −$0.30 | −$0.18 | +39.88% | $10.6M | SEC |
| Q3 2020 | Nov 12, 2020 | $2.93 | −$0.17 | −105.81% | $9.0M | SEC |
Quarterly revenue
Frequently asked questions
When did IDEAYA Biosciences (IDYA) last report earnings?
IDEAYA Biosciences last reported on Aug 5, 2025, covering fiscal Q2 2025.
Did IDYA beat earnings estimates?
No. IDEAYA Biosciences reported EPS of −$0.88 for Q2 2025 against a −$0.78 estimate — a 12.56% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.